IBI 321
Alternative Names: IBI-321Latest Information Update: 28 Aug 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV, Infusion)
- 23 Feb 2023 Innovent Biologics completes a Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT04911881)
- 17 Feb 2023 Innovent Biologics completes a Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT04911894)